Neuroleptic malignant syndrome (NMS): clinical features
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Neuroleptic malignant syndrome (NMS): clinical features. The use or withdrawal of both classical and atypical neuroleptics.
Pathophysiology of NMS
- The use or withdrawal of both classical and atypical neuroleptics
- The use of dopamine-depleting drugs
- The withdrawal of dopaminergic drugs
Onset features
Locked: subscribe to see this section.
Main neurological features
Locked: subscribe to see this section.
Autonomic features
Locked: subscribe to see this section.
Other neurological features
Locked: subscribe to see this section.
Differential diagnosis
Locked: subscribe to see this section.
References
- Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000; 85:129-135.
- Munhoz RP, Moscovich M, Araujo PD, Tieve HAG. Movement disorders emergencies: a review. Arq Neuropsiquiatr 2012; 70:453-461.
- Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000; 85:129-135.
- Ong KC, Chew EL, Ong YY. Neuroleptic malignant syndrome without neuroleptics. Singapore Med J 2001; 42:85-88.
- Lee S, Merriam A, Kim T-S, Liebling M, Dickson DW, Moore GRW. Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury. JNNP 1989; 52:387-391.
- And 1 more. Subscribe to see the full list
